10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2009 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 19, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Cash Flow From (Used in) Operating Activities of Continuing Operations: | |||
| Net earnings | $ 5,745,838 | 4,880,719 | 3,606,314 |
| Less: Gain on sale of discontinued operations | 146,503 | ||
| Earnings from continuing operations | 5,745,838 | 4,734,216 | 3,606,314 |
| Adjustments to reconcile earnings from continuing operations to net cash from operating activities of continuing operations - | |||
| Depreciation | 1,210,977 | 1,051,728 | 1,072,855 |
| Amortization of intangible assets | 878,533 | 787,101 | 782,031 |
| Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture | (797,130) | ||
| Share-based compensation | 366,357 | 347,015 | 429,677 |
| Gain on dissolution of the TAP Pharmaceutical Products Inc. joint venture | (94,248) | ||
| Acquired in-process research and development | 170,000 | 97,256 | |
| Investing and financing (gains) losses, net | 41,967 | 111,238 | 356,331 |
| Trade receivables | (387,749) | (948,314) | (431,846) |
| Inventories | 230,555 | (257,476) | 131,324 |
| Prepaid expenses and other assets | (386,889) | 436,218 | (418,344) |
| Trade accounts payable and other liabilities | (374,715) | 569,056 | (82,960) |
| Income taxes | 577,416 | 160,830 | (261,539) |
| Net Cash From Operating Activities of Continuing Operations | 7,275,160 | 6,994,620 | 5,183,843 |
| Cash Flow From (Used in) Investing Activities of Continuing Operations: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (2,370,630) | (250,000) | |
| Acquisitions of property and equipment | (1,089,048) | (1,287,724) | (1,656,207) |
| Sales of Boston Scientific common stock | 318,645 | 568,437 | |
| Purchases of investment securities | (248,970) | (923,937) | (32,852) |
| Proceeds from sales of investment securities | 16,306 | 130,586 | 17,830 |
| Other | (6,368) | (75,061) | (33,485) |
| Net Cash (Used in) Investing Activities of Continuing Operations | (3,698,710) | (2,087,491) | (1,136,277) |
| Cash Flow From (Used in) Financing Activities of Continuing Operations: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 3,217,331 | (324,739) | (3,603,481) |
| Proceeds from issuance of long-term debt | 3,000,000 | 3,500,000 | |
| Repayments of long-term debt | (2,483,176) | (913,948) | (441,012) |
| Purchases of common shares | (826,345) | (1,081,806) | (1,058,793) |
| Proceeds from stock options exercised, including income tax benefit | 508,669 | 1,008,843 | 1,249,804 |
| Dividends paid | (2,414,460) | (2,174,252) | (1,959,150) |
| Net Cash From (Used in) Financing Activities of Continuing Operations | 1,002,019 | (3,485,902) | (2,312,632) |
| Effect of exchange rate changes on cash and cash equivalents | 118,848 | (115,160) | 200,258 |
| Net cash provided from the sale of discontinued operations | 349,571 | ||
| Net Increase in Cash and Cash Equivalents | 4,697,317 | 1,655,638 | 1,935,192 |
| Cash and Cash Equivalents, Beginning of Year | 4,112,022 | 2,456,384 | |
| Cash and Cash Equivalents, End of Year | 8,809,339 | 4,112,022 | 2,456,384 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |